Skip to main content
Premium Trial:

Request an Annual Quote

N-of-One Inks Deal With NeoGenomics to Interpret Cancer Dx Tests

NEW YORK (GenomeWeb) – Bioinformatics firm N-of-One today announced an agreement with NeoGenomics to interpret the results of tests performed by the cancer genetics diagnostics firm.

Under the agreement, Lexington, Mass.-based N-of-One will provide clinical and interpretive evidence for NeoGenomics' NeoType solid tumor NGS tests, which report the most common and actionable genomic abnormalities in various subtypes of solid tumors.

Financial terms of the agreement were not disclosed.

"NeoGenomics selected N-of-One because of their oncology domain expertise and the flexible and efficient approach to tailoring their interpretation to meet our needs," NeoGenomics Chief Medical Officer Maher Albitar of said in a statement.

Fort Meyers, Fla.-based NeoGenomics is a high-complexity CLIA-certified clinical laboratory that provides a series of cancer testing services, including cytogenetics, FISH, flow cytometry, immunohistochemistry, and molecular genetic testing.

N-of-One provides highly scalable, cost-effective, patient-specific clinical interpretation for oncology testing.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.